Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Finished Drugs	1.16B	1.02B	1.02B	1.14B	1.01B
Finished Drugs Growth	13.98%	-0.34%	-10.16%	12.49%	22.69%
Elimination of Intersegment Sales	-107.06M	-109.32M	-80.63M	-64.64M	-61.42M
Intermediates and Bulk Medicines	177.27M	151.36M	210.05M	205.09M	215.56M
Intermediates and Bulk Medicines Growth	17.11%	-27.94%	2.42%	-4.86%	-15.47%
Total	1.23B	1.06B	1.15B	1.28B	1.17B
Total Growth	16.09%	-7.89%	-9.90%	9.66%	13.75%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Chinese Mainland	1.22B	1.05B	1.13B	1.22B	1.10B
Chinese Mainland Growth	15.96%	-7.53%	-6.92%	10.51%	18.70%
Other Countries	14.45M	11.29M	16.73M	58.94M	62.35M
Other Countries Growth	28.03%	-32.52%	-71.62%	-5.46%	-34.49%
Total	1.23B	1.06B	1.15B	1.28B	1.17B
Total Growth	16.09%	-7.89%	-9.90%	9.66%	13.75%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 13, 2026

Data Sources Report a data error